CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 76 enrolled
Drug / intervention
AcrySof® ReSTOR® Aspheric IOLdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00934622
NCT00934622Phase 4Completed
CompareCT.gov

Visual Function After Implantation of Bilateral AcrySoft ReSTOR Aspheric Intraocular Lens (IOL)

Alcon Research·interventional·Posted Jul 8, 2009·Updated May 6, 2010

In Brief

A Phase 4 clinical trial evaluating AcrySof® ReSTOR® Aspheric IOL for Cataract. Completed, enrolled 76 participants across 1 site.

Detailed Summary

This study will involve up to 20 bilateral patients per surgeon. Patients will be assessed pre-operatively, and at subsequent visits (following the implantation of the intraocular lens in the second eye) at 1 week, 1 month, 3 months and 6 months post-operatively.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 8, 2009
Enrollment StartNov 1, 2007
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.0 years ago

Interventions

AcrySof® ReSTOR® Aspheric IOLdevice

AcrySof® ReSTOR® Aspheric Intraocular Lens (IOL) implanted into the study eye following the cataract extraction surgery